Swiss pharma giant Novartis to close biotech firm Morphosys
Novartis acquired Morphosys earlier this year for a total of €2.7 billion (CHF2.5 billion).
Keystone-SDA
Select your language
Generated with artificial intelligence.
Listening: Swiss pharma giant Novartis to close biotech firm Morphosys
Novartis is closing the German biotech company Morphosys, acquired earlier this year, according to German press reports confirmed by the Basel-based pharmaceutical giant. Hundreds of jobs are affected.
Novartis decided in November 2024 to close the Morphosys sites in Germany and the United States by the end of 2025 and integrate all portfolio activities into the company, according to an article in the German magazine WirtschaftsWoche on Thursday. Around 330 jobs could be lost. Contacted by the AWP news agency, the Basel-based pharmaceutical giant confirmed this information.
Novartis acquired Morphosys earlier this year for a total of €2.7 billion (CHF2.5 billion). With this acquisition, the Basel-based company was hoping to gain access to Pelabresib, a treatment in development for myelofibrosis, a potentially fatal chronic bone marrow disease.
But concerns have recently arisen about the efficacy and safety of this promising drug, according to the German magazine. A few weeks ago, Novartis re-assessed Morphosys and corrected its value by $800 million.
“All merger-and-acquisition activities in research and development involve a certain degree of risk and depend on circumstances. Novartis regularly reviews its portfolio and organizational structure in order to be better positioned for the future and to meet patients’ needs,” the Basel-based pharmaceutical giant explained to WirtschaftsWoche.
Morphosys was founded in 1992 and is one of Germany’s oldest biotech companies. Until recently, the company’s shares were listed in Frankfurt and New York.
Translated from French with DeepL/gw
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Life & Aging
Zurich: how the world capital of housing shortages is tackling the problem
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Ex-sect member sentenced in Zurich for sexual abuse
This content was published on
Zurich District Court has sentenced a former member of the globally active sect "Children of God" to a partial prison sentence.
SNB chairman does not rule out slowdown in Swiss growth
This content was published on
Martin Schlegel, chairman of the Swiss National Bank (SNB), does not rule out a weakening of the Swiss economy in light of the tariff dispute.
Swiss NGOs abroad to receive 10% less federal funding
This content was published on
In 2025 and 2026, Swiss NGOs will have 10% less federal funding available for international cooperation than in the previous two-year period.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.